| Document |
Document Title |
|
WO/2024/085100A1 |
The present disclosure relates to a solid particle dispersed oily preparation. The present disclosure also provides a solid particle dispersed oily preparation suited to eyedrops or intraocular administration. The solid particle disperse...
|
|
WO/2024/086555A1 |
The present disclosure generally relates to methods of treating geographic atrophy (GA), reducing the growth rate of total GA lesion area, slowing the loss of visual acuity, and preventing or slowing development and/or progression of cho...
|
|
WO/2024/083956A1 |
The present invention relates to a formulation of josamycin or a related compound in a crosslinked poly- or oligosaccharide, and the use of this formulation in ophthalmic treatment of infection and fibrosis.
|
|
WO/2024/085081A1 |
Provided is an antibody that specifically binds to the extracellular domain of human LPA1 but does not specifically bind to the extracellular domain of human LPA2 or the extracellular domain of human LPA3. The antibody preferably has act...
|
|
WO/2024/083013A1 |
Disclosed are a human mitochondrial dynamin like GTPase and the use thereof. The gene sequence encoding four variants of the recombinant human type II mitochondrial dynamin like GTPase is optimized, and the experiments on the sequence st...
|
|
WO/2024/086304A1 |
Provided herein are compositions for ophthalmic administration and methods of use.
|
|
WO/2024/006771A3 |
The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compou...
|
|
WO/2024/083176A1 |
Disclosed are the uses of amniotic fluid in the preparation of a drug for treating and/or preventing macrophage-mediated diseases, a drug for treating and/or preventing type M1 macrophage-mediated diseases, a drug for treating and/or pre...
|
|
WO/2024/086182A1 |
The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or m...
|
|
WO/2024/059626A3 |
Provided herein are biopolymers comprising repeating polysaccharide units, preparations of biopolymers, and ophthalmic compositions comprising biopolymers, as well as methods of use.
|
|
WO/2024/079755A1 |
The present disclosure provides a method for obtaining RPE (retinal pigment epithelium) cells from iPSCs (induced pluripotent stem cells) comprising: (a) generating embryoid bodies from a culture of iPSCs, wherein the embryoid bodies are...
|
|
WO/2024/080952A1 |
The present invention relates to usage of hydrogen peroxide compounds as active substance in elimination of diabetic retinopathy diseases and the symptoms resulting from these diseases, and pharmaceutical compositions comprising hydrogen...
|
|
WO/2024/081163A1 |
Provided herein are methods of treating leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL) in a subject in need thereof, the method comprising: administering a therapeutic agent to the subject, wh...
|
|
WO/2024/081442A1 |
Soluble proteins and extracellular vesicles (EVs) produced by optic nerve lamina region neural progenitor cells (ONLR-NPCs) are provided. Such proteins and EVs include growth factors and survival factors that can be used in the treatment...
|
|
WO/2024/077793A1 |
The present invention relates to a compound based on oxidative stress and an anti-amyloid aggregation mechanism, a preparation method therefor, and a use thereof. The compound of the present invention has a structure represented by formu...
|
|
WO/2024/079326A1 |
A composition of oral administration for use in the prevention and/or and treatment degenerative diseases of the eye that it comprises lysates of probiotic micro-organisms in the form of a dry powder of the genus Bacillus, Lactobacillus,...
|
|
WO/2024/078515A1 |
The present invention relates to an ophthalmic pharmaceutical composition containing levamisole, a preparation method therefor, and a use thereof, and in particular relates to an ophthalmic preparation. The ophthalmic preparation compris...
|
|
WO/2024/078124A1 |
Provided in the present invention is the use of a TDGF1 gene in the preparation of a drug for treating aging-related diseases or reversing cell aging. Compared with the prior art, the present invention has the following advantages: the u...
|
|
WO/2024/079449A1 |
The invention relates to a construct and AAV particle comprising a wildtype NDP nucleic acid sequence or a codon-optimised NDP nucleic acid sequence. The invention further relates to products and methods for the treatment of one or more ...
|
|
WO/2024/081410A1 |
In certain embodiments, the invention is directed to a compound of formula (I): wherein; X1 is selected from N or N+Y1; X2 is selected from NH or NY2; X3 is selected from NH or NY3; Y1 is selected from -CH2OCO(OCH2CH2)n1OM1; or -CH2OCO(C...
|
|
WO/2024/074670A1 |
The invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of an USH2A-related disease or condition.
|
|
WO/2024/076577A1 |
An aqueous formulation includes a PEDF-derived short peptide (PDSP); a blend of PVP/PVA in different ratios around 8/2 – 2/8; and a tonicity agent, which is preferably non-ionic. The PDSP is preferably 14-39 amino acids long and has th...
|
|
WO/2024/076697A1 |
Methods are provided to prevent and to treat glaucoma by using Calcium channel blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors, or angiotensin receptor blockers (ARB), and more particularly, to a method to prevent and treat glau...
|
|
WO/2024/074666A1 |
The present invention is in the field of drug delivery. The invention relates to the use of monocarboxylates as ligands for receptors that are present in for instance the retina. These receptors were found to be able to mediate uptake of...
|
|
WO/2024/075625A1 |
Provided is a composition against visual field defect disorders, glaucoma, light-induced eye tissue disorders, and disorders related thereto that can be used as a food, beverage, or drug that can be taken over the long term for preventio...
|
|
WO/2024/074668A1 |
The invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of an USH2A related disease or condition.
|
|
WO/2024/076990A1 |
Described herein are multi-specific antigen binding proteins that bind human fibrin or fibrinogen yC domain and vascular endothelial growth factor, and methods of use thereof. In certain aspects, described herein are pharmaceutical compo...
|
|
WO/2024/075809A1 |
The purpose of the present invention is to provide an antimicrobial agent having reduced allergy properties and containing recombinant psLAAO, and a method for producing this antimicrobial agent. This purpose is solved by an antimicrobia...
|
|
WO/2024/030766A9 |
Provided herein are compositions and formulations for alleviating problems associated with unregulated intraocular pressure (IOP) in an eye comprising the administration of Trabodenoson. Administration of Trabodenoson results in reversin...
|
|
WO/2024/073669A1 |
Provided herein are methods of treating neovascular age-related macular degeneration (nAMD) and diabetic retinopathy (DR) in a subject in need thereof comprising administering an anti-hVEGF treatment and a steroid treatment; wherein the ...
|
|
WO/2024/031024A9 |
Provided herein are compositions including peptides, pharmaceutical preparations thereof, and methods of preventing photoreceptor death therewith and protecting of retinal cells, including, but not limited to, photoreceptors and retinal ...
|
|
WO/2024/068898A1 |
The present invention provides pre-mRNA trans-splicing molecules (RTMs) that are useful for correcting mutations in the OPA1 gene. Also provided are methods of using the RTMs as gene therapy (e.g., ex vivo and in vivo gene therapy) for t...
|
|
WO/2024/071979A1 |
The present invention relates to an ophthalmic composition which comprises brimonidine or a salt thereof, SBE-β-CD or a salt thereof, and xanthan gum, is safe, and has excellent stability and therapeutic effects.
|
|
WO/2024/072882A1 |
Provided herein are vectors including a polynucleotide encoding an α9L9'T protein, pharmaceutical compositions including the vector including a polynucleotide encoding an α9L9'T protein, and methods of use thereof. The methods of use i...
|
|
WO/2024/071349A1 |
The present disclosure provides a suspension-type ophthalmic solution having excellent re-dispersibility. More specifically, the present disclosure provides a water-based suspension preparation containing a first component and a second c...
|
|
WO/2024/065268A1 |
Provided is a single-domain antibody or antigen-binding fragment capable of identifying ANG-2, and a multispecific antibody. The antibody or antigen-binding fragment has a heavy chain variable region as represented by any one of SEQ ID N...
|
|
WO/2024/071348A1 |
The present disclosure provides a suspension ophthalmic solution having exceptional re-dispersibility. More specifically, the present disclosure provides an aqueous suspension containing heat-treated (E)-2-(7-trifluoromethylchroman-4-yld...
|
|
WO/2024/068976A1 |
The present invention relates to new compounds capable of inhibiting the activity of SHP2 phosphatase. Compounds of the invention can be used for the treatment of disorders associated with SHP2 deregulation. The present invention also re...
|
|
WO/2019/043596A9 |
The present invention relates to compositions providing improved substantivity, comfort and/or feel to the eye upon application. The present invention further relates to compositions comprising a cellulose derivative in combination with ...
|
|
WO/2024/069144A1 |
The invention provides means and methods for treating, preventing or reversing retinal degeneration by RNA editing. The methods comprise administering to the subject a vector or a pair of complementary vectors that express a dCaslS-ADARn...
|
|
WO/2024/072793A1 |
The invention provides pyridine carboxamide compounds, pharmaceutical compositions, and their use in treating medical conditions.
|
|
WO/2024/067660A1 |
The present disclosure relates to an aza-fused ring compound, a preparation method therefor, and a use thereof in medicine. Specifically, the present disclosure relates to an aza-fused ring compound represented by general formula (I), a ...
|
|
WO/2024/066780A1 |
Provided are a fusion type adeno-associated virus and a gene delivery effect thereof in the lung and eyes. The fusion type adeno-associated virus comprises a fusion peptide fragment formed by fusion of peptide fragments of serotype AAV1 ...
|
|
WO/2024/069634A1 |
The present invention is directed to compounds and compositions comprising thereof. Further, methods of use such as for the treatment and prevention of cancer in a subject in need thereof are also provided.
|
|
WO/2024/066377A1 |
The present invention provides a VEGF and ANG-2 bispecific antibody and use thereof. The bispecific antibody comprises: a first binding region, the first binding region comprising a single-chain antibody, and the single-chain antibody ha...
|
|
WO/2024/072794A1 |
The invention provides pyridine carboxamide compounds, pharmaceutical compositions, and their use in treating medical conditions.
|
|
WO/2024/069236A1 |
Described herein is a method of treating an individual with inactive thyroid eye disease (TED), the method comprising administering to an individual with inactive or chronic TED an insulin-like growth factor 1 receptor (IGF1R) inhibitor,...
|
|
WO/2024/071959A1 |
The present invention relates to a method for synthesizing a derivative obtained by esterifying choline alfoscerate. The present invention also relates to a preparation comprising a choline alposcerate ester (TGPC) derivative and a use t...
|
|
WO/2024/071370A1 |
The present disclosure provides a cyclic peptide derivative composition for treating or preventing eye disease. The present disclosure relates to: a composition comprising a compound for treating or preventing eye disease; or a pharmac...
|
|
WO/2024/073042A1 |
The present disclosure is directed to compounds and compositions that contain cell penetrating peptides and therapeutic moieties for treating a disease of the eye. The compounds and compositions may be delivered to the eye for treating a...
|
